A Phase I, Open-label, Multicenter, First in Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients with Advanced Malignancies

Trial summary:

This study is evaluating how safe, tolerable and effective a new potential treatment drug called HH3806 is in people with advanced solid cancer or relapsed/refractory non-Hodgkin’s lymphomas.

Receptor status / problem studied:

Inclusion criteria

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

Exclusion criteria

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

View more trial information

Open for recruitment

Trial Title



Advanced solid tumours

Type of trial


Type of treatement

Medical Oncology





Principal Investigator
View all clinical trials


Contact us
Become a patient